BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11599105)

  • 1. Pitfalls in TRAP assay in routine detection of malignancy in effusions.
    Braunschweig R; Guilleret I; Delacrétaz F; Bosman FT; Mihaescu A; Benhattar J
    Diagn Cytopathol; 2001 Oct; 25(4):225-30. PubMed ID: 11599105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of malignant effusions: comparison of a telomerase assay and cytologic examination.
    Braunschweig R; Yan P; Guilleret I; Delacretaz F; Bosman FT; Mihaescu A; Benhattar J
    Diagn Cytopathol; 2001 Mar; 24(3):174-80. PubMed ID: 11241900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase activity in effusions: a comparison between telomere repeat amplification protocol in situ and conventional telomere repeat amplification protocol assay.
    Hansson M; Zendehrokh N; Ohyashiki J; Ohyashiki K; Westman UB; Roos G; Dejmek A
    Arch Pathol Lab Med; 2008 Dec; 132(12):1896-902. PubMed ID: 19061286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomere repeat amplification protocol (TRAP) in situ reveals telomerase activity in three cell types in effusions: malignant cells, proliferative mesothelial cells, and lymphocytes.
    Zendehrokh N; Dejmek A
    Mod Pathol; 2005 Feb; 18(2):189-96. PubMed ID: 15389260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limitations of detection of malignancy in pleural effusions using ELISA-based TRAP assay: comparison with cytological examination.
    Lee WY
    Cytopathology; 2005 Oct; 16(5):227-32. PubMed ID: 16181308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomerase activity analyzed with TRAP in situ provides additional information in effusions remaining equivocal after immunocytochemistry and hyaluronan analysis.
    Adell E; Dejmek A
    Diagn Cytopathol; 2014 Dec; 42(12):1051-7. PubMed ID: 24692425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytological diagnosis and telomerase activity of cells in effusions of body cavities.
    Toshima S; Arai T; Yasuda Y; Takaya T; Ito Y; Hayakawa K; Shibuya C; Yoshimi N; Shibayama M; Kashiki Y
    Oncol Rep; 1999; 6(1):199-203. PubMed ID: 9864428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of NCL-hTERT antibody reactivity and telomere repeat amplification protocol in situ in effusions.
    Zendehrokh N; Rehnberg J; Dejmek A
    Acta Cytol; 2007; 51(6):886-92. PubMed ID: 18077981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression analysis of the catalytic subunit of human telomerase (hEST2) in the differential diagnosis of serous effusions.
    Nagel H; Schlott T; Schulz GM; Droese M
    Diagn Mol Pathol; 2001 Mar; 10(1):60-5. PubMed ID: 11277397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In situ telomerase activity in pleural effusions: a promising marker for malignancy.
    Dejmek A; Yahata N; Ohyashiki K; Ebihara Y; Kakihana M; Hirano T; Kawate N; Kato H
    Diagn Cytopathol; 2001 Jan; 24(1):11-5. PubMed ID: 11135462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytohistological correlation in serous effusions using the newly proposed International System for Reporting Serous Fluid Cytopathology: Experience of an oncological center.
    Lobo C; Costa J; Petronilho S; Monteiro P; Leça L; Schmitt F
    Diagn Cytopathol; 2021 May; 49(5):596-605. PubMed ID: 32339444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase activity in pleural effusions: diagnostic significance.
    Yang CT; Lee MH; Lan RS; Chen JK
    J Clin Oncol; 1998 Feb; 16(2):567-73. PubMed ID: 9469342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of DNA flow cytometry and immunocytochemical analysis in diagnosis of malignant effusions.
    Kundu R; Handa U; Mohan H
    Diagn Cytopathol; 2012 Oct; 40(10):887-92. PubMed ID: 21485027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of the human telomerase RNA component by in situ hybridization in cells from body fluids.
    Nieh S; Chen SF; Fu E; Jan CI; Lee WH
    Acta Cytol; 2005; 49(1):31-7. PubMed ID: 15717752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of molecular genetics to the diagnosis of lymphoid-rich effusions: study of 95 cases with concomitant immunophenotyping.
    Mihaescu A; Gebhard S; Chaubert P; Rochat MC; Braunschweig R; Bosman FT; Delacrétaz F; Benhattar J
    Diagn Cytopathol; 2002 Aug; 27(2):90-5. PubMed ID: 12203875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early diagnosis of mesothelioma in serous effusions using AgNOR analysis.
    Pomjanski N; Motherby H; Buckstegge B; Knops K; Rohn BL; Böcking A
    Anal Quant Cytol Histol; 2001 Apr; 23(2):151-60. PubMed ID: 11332082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of telomerase activity between malignant and tuberculous pleural effusions.
    Maneechotesuwan K; Lertworawiwat A; Tscheikuna J; Wamanuttajinda V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S46-54. PubMed ID: 17718245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of hyperdiploid malignant cells in body cavity effusions by fluoresence in situ hybridization on ThinPrep slides.
    Florentine BD; Sanchez B; Raza A; Frankel K; Martin SE; Kovacs B; Felix JC
    Cancer; 1997 Oct; 81(5):299-308. PubMed ID: 9349518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of DNA flow cytometry and image cytometry on effusion fluid.
    Saha I; Dey P; Vhora H; Nijhawan R
    Diagn Cytopathol; 2000 Feb; 22(2):81-5. PubMed ID: 10649516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Static DNA cytometry as a diagnostic aid in effusion cytology: II. DNA aneuploidy for identification of neoplastic cells in equivocal effusions.
    Motherby H; Nadjari B; Remmerbach T; Marcy T; Pomjanskaja N; Müller W; Knops K; Häussinger D; Strauer BE; Böcking A
    Anal Quant Cytol Histol; 1998 Jun; 20(3):162-8. PubMed ID: 9642442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.